Addition of Cyclophosphamide “On Demand” to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma—A Retrospective Review of a Single-center Experience-Reference-Cited by-同舟云学术

Addition of Cyclophosphamide “On Demand” to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma—A Retrospective Review of a Single-center Experience

Published:2019-04 Issue:4 Volume:19 Page:e195-e203
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Alahmadi Majed,Masih-Khan Esther,Atenafu Eshetu G.^ORCID,Chen Christine,Kukreti Vishal,Tiedemann Rodger,Trudel Suzanne,Reece Donna E.

Funder

Celgene

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference30 articles.

1. New insights into therapeutic targets in myeloma;Anderson;Hematol Am Soc Hematol Educ Program,2011

2. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study;Kumar;Lancet Oncol,2014

3. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma;Dimopoulos;N Engl J Med,2007

4. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma;Dimopoulos;Leukemia,2009

5. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America;Weber;N Engl J Med,2007

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenalidomide in Multiple Myeloma: Review of Resistance Mechanisms, Current Treatment Strategies and Future Perspectives;Cancers;2023-02-02

2. The impact of lenalidomide maintenance on second‐line chemotherapy in transplant eligible patients with multiple myeloma;European Journal of Haematology;2021-02-16

3. Cyclophosphamide/dexamethasone/lenalidomide;Reactions Weekly;2020-06

4. Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma;HemaSphere;2020-04